APR Co. Dives into Biotech with PDRN Anti-Aging Treatments
APR Co., the leading beauty company in South Korea and the proud owner of the MediCube skincare brand, is strategically venturing into the biotechnology sector. The company plans to develop injectable anti-aging treatments using polydeoxyribonucleotide (PDRN). APR Co. has announced its decision to start in-house production of PDRN and polynucleotide materials, marking its entry into the rapidly expanding skin booster business.
PDRN, a compound derived from salmon DNA, has emerged as one of the most sought-after skincare ingredients from South Korea. Known for its cellular repair, hydrating, and anti-inflammatory properties, PDRN was originally used in dermatology clinics. However, it is now increasingly being incorporated into consumer skincare products and professional treatments for anti-aging and skin regeneration.
APR Co. has plans to construct a production facility that spans 1,500 pyeong on a 4,000 pyeong site in Pyeongtaek, Gyeonggi-do. The facility is expected to be completed by the end of 2025. This strategic move positions the company to capitalize on South Korea’s skin booster market. This market was valued at $87.7 million in 2024 and is projected to grow at a 16.1% CAGR through 2030. PDRN is expected to register the fastest growth rate in this market.
Source: Grand View Research